Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
6.63
Dollar change
-0.30
Percentage change
-4.34
%
Index- P/E- EPS (ttm)-2.85 Insider Own18.15% Shs Outstand4.54M Perf Week16.93%
Market Cap32.42M Forward P/E- EPS next Y- Insider Trans0.60% Shs Float4.00M Perf Month40.47%
Income-12.94M PEG- EPS next Q- Inst Own41.83% Short Float0.82% Perf Quarter102.75%
Sales0.00M P/S- EPS this Y- Inst Trans-11.08% Short Ratio0.83 Perf Half Y330.52%
Book/sh2.47 P/B2.69 EPS next Y- ROA-64.61% Short Interest0.03M Perf Year410.00%
Cash/sh2.47 P/C2.68 EPS next 5Y2.10% ROE-76.36% 52W Range1.01 - 7.12 Perf YTD117.48%
Dividend Est.- P/FCF- EPS past 5Y37.03% ROI-115.56% 52W High-6.88% Beta2.21
Dividend TTM- Quick Ratio7.88 Sales past 5Y0.00% Gross Margin- 52W Low556.44% ATR (14)0.48
Dividend Ex-Date- Current Ratio7.88 EPS Y/Y TTM56.30% Oper. Margin0.00% RSI (14)65.15 Volatility12.62% 8.17%
Employees6 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price9.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q71.31% Payout- Rel Volume0.57 Prev Close6.93
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume39.88K Price6.63
SMA2018.52% SMA5032.69% SMA200145.49% Trades Volume22,865 Change-4.34%
Date Action Analyst Rating Change Price Target Change
Jul-24-17Initiated William Blair Outperform
Jul-24-17Initiated Jefferies Buy $20
Jul-24-17Initiated BofA/Merrill Buy $19
Mar-12-24 08:00AM
Feb-15-24 04:05PM
Feb-01-24 04:30PM
Oct-31-23 12:30PM
Apr-04-23 09:55AM
09:55AM Loading…
Mar-14-23 09:55AM
Feb-22-23 11:49AM
Feb-21-23 02:50PM
08:30AM
Dec-29-22 12:00PM
Nov-30-22 07:00AM
Nov-24-22 09:55AM
Nov-10-22 08:00AM
Nov-04-22 12:00PM
Nov-01-22 08:15AM
06:05AM Loading…
Oct-26-22 06:05AM
Sep-30-22 08:41AM
Sep-22-22 08:00AM
Sep-06-22 07:00AM
Aug-15-22 04:15PM
Aug-01-22 07:51AM
Jul-08-22 08:31AM
Jun-29-22 09:46AM
06:30AM
May-19-22 07:00AM
06:40AM
May-17-22 07:00AM
May-13-22 07:00AM
May-11-22 07:57AM
May-10-22 12:43PM
04:15PM Loading…
May-05-22 04:15PM
Apr-21-22 09:40AM
08:00AM
Apr-05-22 09:40AM
Mar-28-22 04:20PM
Mar-22-22 08:04AM
Jan-27-22 01:38PM
Jan-05-22 08:04AM
Jan-04-22 08:45AM
07:00AM
Dec-30-21 04:32AM
Dec-20-21 10:56AM
Nov-12-21 07:50AM
Oct-07-21 09:22AM
Sep-30-21 04:30PM
Sep-16-21 02:33PM
08:15AM
Sep-10-21 08:30AM
Sep-07-21 04:05PM
Aug-27-21 09:48AM
07:45AM
Aug-11-21 04:20PM
Jul-08-21 08:15AM
Jul-01-21 01:39PM
08:00AM
Jun-30-21 09:33AM
Jun-24-21 07:00AM
May-19-21 07:00AM
May-11-21 04:18PM
Mar-24-21 04:36PM
Mar-04-21 08:30AM
Mar-02-21 07:00AM
Jan-11-21 06:30AM
Jan-06-21 09:30AM
Dec-23-20 03:41AM
Dec-21-20 08:00AM
Dec-14-20 08:32AM
Dec-01-20 10:12AM
Nov-29-20 08:33PM
Nov-24-20 08:28AM
Nov-19-20 10:02AM
Nov-12-20 07:03PM
Oct-24-20 04:35AM
Oct-20-20 09:24AM
Oct-13-20 08:30AM
Oct-12-20 07:00AM
Sep-21-20 06:07PM
Sep-10-20 08:45AM
Aug-25-20 01:25PM
Aug-05-20 04:10PM
Aug-04-20 03:31PM
Aug-03-20 08:10AM
08:00AM
Jun-29-20 08:30AM
Jun-12-20 11:42AM
Jun-10-20 09:54AM
Jun-04-20 09:15AM
Jun-03-20 04:01PM
Jun-02-20 10:22AM
07:45AM
Jun-01-20 08:34AM
07:00AM
May-27-20 08:30AM
May-11-20 08:30AM
Apr-22-20 08:30AM
Mar-30-20 04:16PM
Dec-20-19 05:45PM
Dec-19-19 06:07AM
Dec-18-19 08:30AM
Nov-07-19 07:30AM
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WINDSOR JAMES BRIANPresident and COODec 15 '23Buy3.37225758225Dec 18 05:56 PM
WINDSOR JAMES BRIANPresident and COONov 20 '23Buy1.975,0769,9875,122Nov 21 04:43 PM